Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study

What Was Tested

This clinical trial paper looks at Somatostatin.

The aim was to test the feasibility and advantages of doing RGS using a gallium-68 labeled with somatostatin receptor analogs in the intraoperative detection of neuroendocrine tumors.

Who Took Part

According to the abstract, 9 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Ga-68 somatostatin receptor PET/CT imaging was performed preoperatively in 9 patients with gastroenteropancreatic neuroendocrine tumors.

How the Study Was Run

The researchers set it up as a pilot study.

It is described as a pilot, a small early test of whether a larger Somatostatin study would be practical.

Statistical analyses were performed to find out the correlation between the pathologic size of the tumor lesions and the maximum standardized uptake value on PET/CT as well as the target/nontarget ratio (T/NT) of gamma probe counts.

Thereafter, the impact of the planned operation procedure and the lesion-based sensitivity of tumor detection (surgical palpation vs.

PET/CT vs. gamma probe) had been observed.

What Was Measured

PubMed files the paper under topics including Gallium Radioisotopes, Multimodal Imaging, Neuroendocrine Tumors, Pilot Projects, Positron-Emission Tomography, Radiosurgery and Somatostatin.

What This Means in Plain Language

The paper is a pilot study of Somatostatin in 9 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (Clinical nuclear medicine), a journal based in United States.

More context: the Somatostatin compound page, all human trials.